Principal Investigator
Jaime Merchan
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20260409
Clinical Trial Summary
An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
+1 (407) 7659589